Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemoimmunotherapy for multiple myeloma

R Alexanian, S Salmon, J Gutterman

    Cancer
    |April 15, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    How fast is fast enough? Academic behavioural science impacting public health policy and practice.

    Public health·2023
    Same author

    Pre-Flight Calibration of the Mars 2020 Rover Mastcam Zoom (Mastcam-Z) Multispectral, Stereoscopic Imager.

    Space science reviews·2021
    Same author

    Immunohistochemical Characterization of Sarcomas in Trp53+/- Haploinsufficient Mice.

    Toxicologic pathology·2017
    Same author

    Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
    Same author

    A comparison of uptake of strontium 90 and cesium 137 by bryophytes and vascular plants.

    Annual progress report - University of California, Laboratory of Nuclear Medicine and Radiation Biology·2014
    Same author

    Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2013
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Chemoimmunotherapy consolidation with alkylating agents and BCG showed no survival benefit for multiple myeloma patients. Bacillus Calmette-Guerin (BCG) did not improve outcomes in this study.

    Area of Science:

    • Oncology
    • Immunotherapy

    Background:

    • Multiple myeloma is a hematologic malignancy.
    • Chemoimmunotherapy is a treatment approach combining chemotherapy and immunotherapy.

    Purpose of the Study:

    • To evaluate the efficacy of chemoimmunotherapy consolidation using alternating courses of alkylating agents and Bacillus Calmette-Guerin (BCG) in multiple myeloma patients.
    • To assess the impact of BCG on survival and remission duration.

    Main Methods:

    • A study involving 105 responding multiple myeloma patients.
    • Alternating courses of alkylating agents and BCG were administered as consolidation treatment.
    • Patient survival and remission duration were compared to historical controls.

    Main Results:

    Related Experiment Videos

  • No significant difference in survival time was observed compared to previous maintenance programs.
  • Bacillus Calmette-Guerin (BCG) demonstrated no apparent value in improving outcomes for multiple myeloma.
  • Longest unmaintained remission duration was associated with low residual plasma cells.
  • Relapse typically occurred within one year in patients with persistent serum myeloma peaks.
  • Disease recontrol was achieved in 50% of relapsing patients, with a median survival of 20 months from retreatment.

    • Conclusions:

    • Chemoimmunotherapy consolidation with alternating alkylating agents and BCG does not appear to offer additional survival benefits for multiple myeloma patients.
    • Management strategies should consider patient-specific factors like residual plasma cell counts and myeloma protein levels for optimizing follow-up and retreatment decisions.